Fennec Pharmaceuticals Inc.
TSX:FRX.TOBiotechnology
-$0.22 today
- Market cap
- $676.80M
- Beta
- 1.08
- P/E (TTM)
- -36.5
- EPS (TTM)
- -$0.24
Volume 0.00M
Average 0.00M
FRX.TO Operating Cash Flow
Cash generated by the company's core business operations during the period.
Fennec Pharmaceuticals Inc.TSX: FRX.TO
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow turns positive
Q1 FY2026 operating cash flow was $2.37M, compared with -$4.32M a year earlier. Trailing-twelve-month operating cash flow was -$7.86M. Over 3 fiscal years it compounded at -6.7% a year.
Context
- Operating cash flow amounted to 32.9% of revenue in FY2025, down 23.9 pp from a year earlier.
- Operating cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly operating cash flow holds near $2.37M or moves back toward the trailing-twelve-month quarterly average of -$1.97M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (14.67M) USD
- Year-over-year change
- -154.4%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (14.67M) | -154.4% |
| FY2024 | 2024-12-31 | 26.98M | +257.4% |
| FY2023 | 2023-12-31 | (17.14M) | +5.1% |
| FY2022 | 2022-12-31 | (18.06M) | -27.0% |
| FY2021 | 2021-12-31 | (14.22M) | — |
Operating Cash Flow vs competitors
How FRX.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -52.0% is the 7th highest of 8, against a peer median of -33.2%.
- Operating cash flow amounts to 15.4% of revenue for FRX.TO, versus a peer median of 16.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$70.9M CAD | -57.2% | -51.4% | 22.8% | |
| LTM Mar 2026 | $48.89M USD | -34.4% | -6.9% | 16.0% | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | $38.32M USD | +43.9% | +14.6% | 204.3% |
| LTM Mar 2026 | $31.41M USD | +15.5% | +15.7% | — | |
| LTM Mar 2026 | $22.04M USD | -33.2% | — | 8.4% | |
| LTM Mar 2026 | CA$9.01M CAD | -42.3% | — | 3.3% | |
| LTM Mar 2026 | $7.86M USD | -52.0% | -6.7% | 15.4% | |
| LTM Apr 2026 | CA$3.21M CAD | -18.4% | -16.2% | — | |
| Peer median (excluding FRX.TO) | — | -33.2% | -6.9% | 16.0% | |
Competitors are the stored peer set for FRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.35M) | (23.71M) | (16.05M) | (436K) | (9.74M) |
| Depreciation & Amortization | 0 | 0 | 0 | 800K | 103K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.02M | 4.22M | 5.35M | 5.06M | 7.03M |
| Change in Working Capital | (932K) | 1.1M | (6.78M) | 16.94M | (12.04M) |
| Accounts Receivables | 0 | (1.55M) | (7.27M) | (7.87M) | (12.44M) |
| Inventory | 0 | (576K) | (1.58M) | 579K | (1.28M) |
| Accounts Payables | (794K) | 1.61M | 1.39M | (537K) | 1.39M |
| Other Working Capital | (138K) | 1.61M | 683K | 24.77M | 282K |
| Other Non-Cash Items | 307K | 466K | 326K | 4.61M | (26.45K) |
| Operating Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (14.67M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 5M | 19.94M | 5M | (13M) | (19.82M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 45.01M |
| Common Stock Repurchased | 0 | (194K) | (78K) | (176K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (22K) | 797K | 1.64M | (439K) | (190.27K) |
| Financing Cash Flow | 4.98M | 20.73M | 6.64M | (13.62M) | 25.01M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (1.5M) |
| Net Change in Cash | (9.24M) | 2.67M | (10.51M) | 13.37M | 8.83M |
| Free Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (14.67M) |
Fennec Pharmaceuticals Inc.
TSX:FRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$19.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.